Denali Therapeutics
DNLI
217 hedge funds and large institutions have $3.69B invested in Denali Therapeutics in 2024 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 79 increasing their positions, 59 reducing their positions, and 21 closing their positions.
72% more call options, than puts
Call options by funds: $2.01M | Put options by funds: $1.17M
71% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 21
34% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 59
28% more capital invested
Capital invested by funds: $2.88B → $3.69B (+$815M)
7% more funds holding
Funds holding: 203 → 217 (+14)
1.65% more ownership
Funds ownership: 86.88% → 88.53% (+1.7%)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$188M |
| 2 |
UBS AM
Chicago,
Illinois
|
+$36M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$25.5M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$22.4M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$19.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TPC
Takeda Pharmaceutical Company
Tokyo,
Japan
|
-$97.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$17.8M |
| 3 |
Millennium Management
New York
|
-$13.9M |
| 4 |
YCM
Yiheng Capital Management
San Francisco,
California
|
-$13.6M |
| 5 |
AG
Artal Group
Luxembourg
|
-$11.7M |
DNLI Hedge Fund Activity: Q3 2024 in Review
217 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q3 2024, worth a combined $3.69B — up 28% from $2.88B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new DNLI positions and 21 closed out — a net gain of 15 holders — while 79 added to existing stakes and 59 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $188M. The largest seller was Takeda Pharmaceutical Company, exiting entirely with an estimated $97.9M sold.
- 217 institutional investors held Denali Therapeutics (DNLI) as of Q3 2024, up from 203 in Q2 2024.
- Funds reported $3.69B of Denali Therapeutics stock for Q3 2024, up 28% quarter-over-quarter.
- 36 funds opened new Denali Therapeutics positions in Q3 2024 and 21 closed out, a net change of +15 holders.
- The largest Denali Therapeutics buyer in Q3 2024 was Fidelity Investments, an estimated $188M added.
- The largest Denali Therapeutics seller in Q3 2024 was Takeda Pharmaceutical Company, an estimated $97.9M sold.
Based on aggregated 13F filings for Q3 2024.